APOA1 and neoplasm: Conversely, the intratumoral injection of ADV-ApoA1 can reprogram the lipid metabolism of the GBM tumor microenvironment, modulate cholesterol efflux, restore TAMs’ phagocytosis, and reactivate TAM-T cell anti-tumor immunity.